28 Health economic analysis of low-dose methoxyflurane (LDM) for the treatment of moderate-to-severe trauma pain in sweden

Aim Inadequately treated trauma pain can lead to prolonged and unnecessary patient suffering, as well as lengthen hospital stay. 1,2 LDM (Penthrox®) is an inhaled analgesic indicated for emergency relief of moderate-to-severe pain in conscious adult patients with trauma and associated pain. 3 The aim of this study was to assess the impact of introducing LDM in the pre-hospital setting for a European healthcare system. Method A health economic model was developed from the Swedish healthcare system perspective to evaluate outcomes and resource use associated with LDM vs standard of care (morphine injection, fentanyl nasal spray and ketamine injection) over a 5 year time horizon. Model inputs included time to first pain medication treatment, drug acquisition, administration and equipment costs, practitioner rates and adverse event costs. Inputs were derived from published data supplemented by the results of a retrospective chart review and physician survey. Results Based on a national Swedish population of ~10 M individuals, the model estimated that ~6 00 000 patients would be eligible for LDM treatment in Year 1. Introducing LDM at a 1% uptake rate in Year 1, increasing 1% annually, was estimated to result in the avoidance of ~15,600 hours of moderate-to-severe pain over 5 years, allowing for the treatment of an additional ~43 000 patients for moderate-to-severe pain. A modest cumulative 5 year budget impact increase is estimated at SEK~1 M. Conclusion Introducing LDM as a treatment for moderate-to-severe trauma pain in the pre-hospital setting may result in fewer hours of patient pain and more patients treated at a modest budget increase. References . Sinatra R. Pain Med2010;11(12):1859–71. . Sokolof C, et al. BMJ Open2014;4:e004288. . PENTHROX 3mL inhalation vapour, liquid. PENTHROX 3mL inhalation vapour, liquid 2017. Available from: https://www.medicines.org.uk/emc/medicine/31391 (accessed 19 April 2017) Conflict of interest None Funding Mundipharma International Ltd